Hypothyroidism - Dawn Ipsen, PharmD (2021 Conference) (LDN, low dose naltrexone)

Dr. Dawn Ipsen is a compounding pharmacist who presents on some roles low dose naltrexone (LDN) may have in helping patients with hypothyroidism. She discusses hypothyroidism, its prevalence, and treatment goals. 

Developing outcome centric, territory-specific access protocols for the provision of niche product - John Bardsley (2021 Conference) (LDN, low dose naltrexone)

John Bardsley is managing director of Thistle Pharma Ltd. LDN is an unlicensed medicine. Much of what he is talking about pertains specifically to the UK sector, and may apply to your own territories as well.

History, Pharmacology and Mechanism - Stephen Dickson, BSC (hons) MRPharmS (2021 Conference) (LDN, low dose naltrexone)

LDN Research Trust 2021 Conference - Friday Morning

LDN 2017 Conference - Sunday Q&A (2017 Conference) (LDN, low dose naltrexone)

LDN 2017 Conference - Saturday Afternoon Q&A (2017 Conference) (LDN, low dose naltrexone)

LDN 2017 Conference - Saturday Morning Q&A (2017 Conference) (LDN, low dose naltrexone)

LDN 2017 Conference - Friday Afternoon Q&A (2017 Conference) (LDN, low dose naltrexone)

LDN 2017 Conference - Friday Morning Q&A (2017 Conference) (LDN, low dose naltrexone)

Stephen Dickson, BSC (hons) MRPharmS - Using an Old Drug to Trick the Immune System into Healing Itself (2018 Conference) (LDN, low dose naltrexone)

Angus Dalgleish, MD - The Role of LDN in the Management of Cancer (2017 Conference) (LDN, low dose naltrexone)

Prof. Angus Dalgleish: Well, I'm going to talk about LDN and cancer, and I'm coming from a very different, way of doing things. I was trained in some of my research at the Institute of Cancer Research, where you basically design drugs, put them in mice.